Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22507148 | 0.90 | ACACB (0.58) | KMT2ACA1CA2PARP10MEN1 | |
| SCHEMBL6548631 | 0.88 | CA1 (0.64) | KMT2ACA1CA2PARP10MEN1 | |
| SCHEMBL6285461 | 0.86 | CA1 (0.62) | KMT2ACA1CA2PARP10MEN1 | |
| SCHEMBL31343186 | 0.86 | KMT2A (0.68) | KMT2ACA1CA2PARP10MEN1 | |
| SCHEMBL24943239 | 0.85 | CA1 (0.60) | KMT2ACA1CA2MEN1MAPT | |
| SCHEMBL6616955 | 0.85 | CA1 (0.60) | KMT2ACA1CA2MEN1MAPT | |
| SCHEMBL4368311 | 0.84 | CA12 (0.66) | KMT2ACA1CA2PARP10MEN1 | |
| SCHEMBL8984330 | 0.84 | KMT2A (0.66) | KMT2APARP10MEN1MAPTSMN1; SMN2 | |
| SCHEMBL4261434 | 0.83 | MEN1 (0.71) | KMT2ACA1CA2MEN1MAPT | |
| SCHEMBL28583976 | 0.83 | KMT2A (0.67) | KMT2ACA1CA2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573453-B | Selective of Carboxylic ester cleavage process | 荆楚理工学院 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024103126-A1 | TSPO LIGANDS | THE UNIVERSITY OF SYDNEY (AU) | 2024-05-23 | — | — | WO | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| CN-114315844-B | FXR regulator and preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-27 | — | — | CN | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| CN-114573453-A | Selective carboxylic ester cracking method | 荆楚理工学院 | 2022-06-03 | — | — | CN | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| WO-2008134734-A2 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008106657-A2 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC | 2008-06-19 | — | — | US | disclosed |
| CN-101023057-A | Certain chemicals, compositions, and methods | CYTOKINETICS INC (US) | 2007-08-22 | — | — | CN | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| WO-2006012504-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | DAIAMED, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-4444567-A | ALKOXY BENZALDEHYDES, ALKOXY BENZOATES | PHILLIPS PETROLEUM COMPANY (US) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | KMT2A 978/4885CA1 2706/4885CA2 1527/4885 |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | F2, SERPINC1, PLAT | KMT2A 3424/4885CA1 1605/4885CA2 1666/4885 |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | KMT2A 1411/4885CA1 1194/4885CA2 988/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | KMT2A 3544/4885CA1 4238/4885CA2 4222/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | KMT2A 4024/4885CA1 4870/4885CA2 4606/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | KMT2A 4024/4885CA1 4870/4885CA2 4606/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | KMT2A 4024/4885CA1 4870/4885CA2 4606/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | KMT2A 4024/4885CA1 4870/4885CA2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.